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Abstract
We report a series of Staphylococcus argenteus infections from Saarland, Germany. Travel histories were unremarkable for
extra-European sojourns, indicating an autochthonous transmission mode. Multilocus sequence typing revealed that all isolates
were members of the clonal complex CC2250. In only one case, guideline-adherent treatment with an isoxazolyl penicillin was
prescribed. Our report illustrates the perils of novel species designations, which may lead to misconceptions and suboptimal
treatment choices among clinicians.
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Introduction
In 2015, a former member of the Staphylococcus aureus lineage
called clonal complex (CC) 75 was delimited as an independent
species called Staphylococcus argenteus [1]. Its identification in
routine diagnostics has only recently become accurate with the
update of commercial databases used for matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) [2, 3]. There have been conflicting reports
on its pathogenicity compared to S. aureus [4–6]. Most data
originate from Asia, Australia, and the Amazon region [6, 7],
while reports from Europe are scarce [8], leaving a need for
reliable epidemiological and clinical data.
Methods
We searched our laboratory information system database for
all identifications of S. argenteus and S. aureus between
October 2018 and December 2019 in clinical samples
(excluding surveillance screenings). All specimens were
handled according to standard microbiological procedures.
Isolates were identified by MALDI-TOF MS using
Microflex LT mass spectrometer (Bruker Daltonics,
Bremen, Germany). Antimicrobial susceptibility testing
(AST) was performed using VITEK II (BioMérieux,
Marcy l’Étoile, France) and interpreted according to the
guidelines of the European Committee on Antimicrobial
Susceptibility Testing (EUCAST, version 9.0). Multilocus
sequence typing (MLST) was performed using FastStart
High Fidelity PCR System (Roche, Germany) and primers
as described previously [6, 9, 10]. Sequence types (ST)
were assigned using the S. aureus MLST Database website
(https://pubmlst.org/saureus/). Patients with an infection, as
opposed to colonization, with S. argenteus were identified
through the clinical microbiologist’s documentation. A chart
review was performed on infected patients using the
hospital information system. Written informed consent was
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A 58-year-old male with hydrocephalus presented due to
protracted wound healing adjacent to the ventriculoperitoneal
(VP) shunt, which had been placed 3 months earlier. C-
reactive protein (CRP) was 6.6 mg/L. Wound opening and
debridement yielded purulent discharge, and the VP shunt
was removed. Cultures from intraoperative wound swabs
and cerebrospinal fluid (CSF) grew S. argenteus .
Intravenous cefuroxime was initiated empirically and a new
VP shunt was implanted after three consecutive, sterile CSF
cultures. The patient improved quickly and was discharged
after 16 days of intravenous therapy. Oral cefuroxime was
maintained for another 5 days. No other infection occurred
during an 8-month follow-up.
Patient #2
A 60-year-old male with esophageal adenocarcinoma was
hospitalized because of dyspnea, malaise, and pain at the exit
site of his port catheter. On physical examination, a painful
redness of the port site was noted. Systolic blood pressure was
70 mmHg, quickly responding to volume resuscitation.
Laboratory examination showed a CRP of 279 mg/L. Due to
a suspected central-line-associated bloodstream infection
(CLABSI), the port system was explanted. A wound swab
and the catheter tip grew S. argenteus, while blood cultures
remained sterile. After a 16-day course of intravenous pipera-
cillin/tazobactam, the patient improved, and a peripherally
inserted central catheter (PICC) was placed. Three months
later, he presented with a painful redness of the PICC entrance
site. The PICC was removed, and oral clindamycin was
started. S. argenteus grew from the catheter tip and in blood
culture, alongside Bacillus cereus, Enterobacter cloacae com-
plex, and Enterococcus faecalis. The patient was started on
intravenous flucloxacillin and meropenem. Follow-up blood
cultures remained sterile, and a transesophageal echocardiog-
raphy revealed no pathologies. After 14 days, he was
discharged home in a good condition. A follow-up period of
3 months has been unremarkable since.
Patient #3
An 80-year-old male was referred for evaluation of pain in his
right hand after previous surgery. On examination, the surgi-
cal site was unremarkable. CRPwas 148mg/L. Blood cultures
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Fig. 1 Colonies of
Staphylococcus argenteus after
24 h of incubation at 35 °C, on
blood agar (a) and chocolate agar
(b), in comparison to
Staphylococcus aureus, on blood
(c) and chocolate agar (d)
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were collected before starting intravenous cefuroxime and be-
came positive with S. argenteus. Following rapid improve-
ment, the patient was transferred back to the referring hospital
after 3 days. The therapy was switched to flucloxacillin, ac-
cording to AST results. One month later, the patient was re-
admitted due to back pain and elevated inflammation markers.
Magnetic resonance imaging of the spine confirmed vertebral
osteomyelitis with intraspinal empyema. The patient
underwent neurosurgery and escalation of antimicrobial ther-
apy tomeropenem and vancomycin. All microbiological spec-
imens obtained during surgery remained sterile. The patient
received intravenous flucloxacillin followed by oral
clindamycin for 6 weeks each. No other infectious complica-
tions were noted during a follow-up of 6 months.
Patient #4
A 52-year-old female presented with unilateral otorrhea and
decreased hearing. She suffered from chronic external otitis
during the ten preceding years. The auditory canal was swol-
len, with yellowish secretion and scaling of the meatus. A
swab from the ear grew S. argenteus. A 1-week course of oral
clindamycin and topical ofloxacin was initiated, leading to
Table 1 Minimal inhibitory concentrations (MIC; in mg/L) of S. argenteus isolates detected in clinical specimens in Homburg, Germany, between
October 2018 and December 2019. MICs are given either as indicated or as smaller or equal to (≤); *Cotrimoxazole MIC 10 mg/L
Antimicrobial agent Number of isolates with indicated MIC Susceptible Resistant
0.12 0.25 0.5 1 2 4 8 16 32 64
Penicillin G 5 3 5/8 (62.5%) 3/8 (37.5%)
Flucloxacillin 3 5 8/8 (100%) –
Gentamicin 8 8/8 (100%) –
Ciprofloxacin 7 1 8/8 (100%) –
Moxifloxacin 8 8/8 (100%) –
Erythromycin 7 1 8/8 (100%) –
Clindamycin 8 8/8 (100%) –
Linezolid 1 7 8/8 (100%) –
Daptomycin 3 5 8/8 (100%) –
Vancomycin 4 4 8/8 (100%) –
Tigecyclin 8 8/8 (100%) –
Fosfomycin 3 3 1 1 7/8 (87.5%) 1/8 (12.5%)
Fusidic acid 8 8/8 (100%) –
Cotrimoxazole 8* 8/8 (100%) –
Table 2 Primers used for MLST
Locus Primer name Primer sequence (5′-3′) Reference
arcC arcC-Up TTGATTCACCAGCGCGTATTGTC [9]
arcC-Dn AGGTATCTGCTTCAATCAGCG
aroE aroE745-up TTATCACCGTCGATGCATAGTGCA [10]
aroE255-down CGGAGTAGTATTTATCACAATATC
glpF glpF-Up CTAGGAACTGCAATCTTAATCC [9]
glpF-me-r CCGGCAATTGGTCCTAAGAT [6]
gmk gmk-Up ATCGTTTTATCGGGACCATC [9]
gmk-me-r AGTGCTCAGCTTCTACAATACA [6]
pta pta-Up GTTAAAATCGTATTACCTGAAGG [9]
pta-Dn GACCCTTTTGTTGAAAAGCTTAA
tpi tpi-Up TCGTTCATTCTGAACGTCGTGAA [9]
tpi-Dn TTTGCACCTTCTAACAATTGTAC
yqiL yqiL-Up CAGCATACAGGACACCTATTGGC [9]
yqiL-Dn CGTTGAGGAATCGATACTGGAAC
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some clinical improvement, with a long-term follow-up visit
of 6 months still pending.
Identification and characterization of Staphylococcus
argenteus isolates
Apart from the patients described, S. argenteus was detected
in four other patients from skin swabs (n = 3) and central ve-
nous catheter tip (n = 1), all of which were deemed as coloni-
zation. During the study period, a total number of 1013
S. aureus isolates were identified. Thus, the ratio of
S. argenteus to S. aureus detections was 0.8%. None of the
four infected patients had a recent travel history outside
Europe (patient #2 reported travels to Belgium and France
2 years earlier).
On blood and chocolate agars, S. argenteus grew in large,
white-grayish colonies with strong beta-hemolysis and a lack
of pigment in comparison to S. aureus (Fig. 1 a–d). AST
showed no methicillin-resistant isolates (Table 1).
All eight isolates were identified as belonging to CC2250
by MLST (Table 2). Specifically, seven isolates were identi-
fied as ST2250, while one isolate revealed a new pta allele
with a G237T point mutation that was designated as a new
sequence type ST5869. None of the eight S. argenteus isolates
was tested positive for panton-valentine leucocidin, as tested
by the GenoType Staphylococcus assay (Bruker-Hain-
Lifescience, Germany).
Conclusions
Our report on patients with S. argenteus infections points to a
likely autochthonous acquisition in Germany, due to the lack
of a recent travel history. Previous literature from high-
prevalence settings indicated that S. argenteus accounts for
4–5% of all S. aureus strains detected in clinical samples
[6], which is higher than in Europe (< 1%) [8, 11]. The ratio
observed at our institute (0.8%) is in line with other European
countries. Similarly, all of our isolates belonged to CC2250,
which is among the most frequent clonal complexes [3].
Our data confirm the pathogenicity of S. argenteus and ex-
tend the spectrum of disease to foreign-body infections. In anal-
ogy to S. aureus bacteraemia, isoxazolyl-penicillins have been
used to treat S. argenteus infections [5]. The observation that
only one patient received flucloxacillin at the initial infection
shows that the designation as a “different” staphylococcal spe-
cies may have mislead clinicians towards a potentially subop-
timal treatment, whichmay be associated with worse outcomes.
In anticipation of such misinterpretations, the ESCMID Study
Group on Staphylococci and Staphylococcal Diseases proposed
to specifically add the remark “member of the S. aureus com-
plex” on the microbiology report, in addition to the immediate
notification of the clinician [3].
Our report contributes to the understanding of S. argenteus
and calls for an increased awareness among microbiologists
and clinicians. Further studies pertaining to S. argenteus
should aim at elucidating its clinical relevance, epidemiology,
and potential for nosocomial transmission and endogenous
infections.
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